Guidance, NICE advice and quality standards In development

Skip to filters Skip to results

Showing 351 to 356 of 356

Sort by

Type: GuidanceRemove Type: Guidance filter
Type: Quality standardRemove Type: Quality standard filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter
Guidance programme: Clinical guidelinesRemove Guidance programme: Clinical guidelines filter
Guidance programme: Interventional procedures guidanceRemove Guidance programme: Interventional procedures guidance filter
Guidance programme: Diagnostics guidanceRemove Guidance programme: Diagnostics guidance filter
Guidance programme: Highly specialised technologies guidanceRemove Guidance programme: Highly specialised technologies guidance filter
Guidance programme: Antimicrobial prescribing guidelinesRemove Guidance programme: Antimicrobial prescribing guidelines filter
Guidance programme: Cancer service guidelinesRemove Guidance programme: Cancer service guidelines filter
Guidance programme: Medicines practice guidelinesRemove Guidance programme: Medicines practice guidelines filter
Guidance programme: Safe staffing guidelinesRemove Guidance programme: Safe staffing guidelines filter
Guidance programme: Social care guidelinesRemove Guidance programme: Social care guidelines filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Women's and reproductive health guidelines	NICE guideline	TBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]	Technology appraisal guidance	TBC
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]	Technology appraisal guidance	17 July 2024
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]	Technology appraisal guidance	TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]	Technology appraisal guidance	7 August 2024
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]	Technology appraisal guidance	23 October 2024

Results per page

10
25
50
All